The Latest Headlines at American Banking and Market News
Exscientia (NASDAQ:EXAI) Given “Equal Weight” Rating at Morgan Stanley
Morgan Stanley reaffirmed their equal weight rating on shares of Exscientia (NASDAQ:EXAI – Free Report) in a research note issued to investors on Monday morning, Benzinga reports. They currently have a $7.00 target price on... More of this article »
enGene (NASDAQ:ENGN) Coverage Initiated by Analysts at Wells Fargo & Company
Wells Fargo & Company assumed coverage on shares of enGene (NASDAQ:ENGN – Free Report) in a research report sent to investors on Monday morning, Marketbeat Ratings reports. The brokerage issued an overweight rating and a... More of this article »
Exelon (NASDAQ:EXC) Given New $37.00 Price Target at Scotiabank
Exelon (NASDAQ:EXC – Free Report) had its price target reduced by Scotiabank from $39.00 to $37.00 in a research note issued to investors on Monday, Benzinga reports. Scotiabank currently has a sector perform rating on the stock. A... More of this article »
Edgewise Therapeutics (NASDAQ:EWTX) Price Target Increased to $32.00 by Analysts at Royal Bank of Canada
Edgewise Therapeutics (NASDAQ:EWTX – Free Report) had its price objective lifted by Royal Bank of Canada from $28.00 to $32.00 in a research report report published on Monday morning, Benzinga reports. Royal Bank of Canada currently... More of this article »
89bio (NASDAQ:ETNB) Receives “Buy” Rating from Bank of America
Bank of America reissued their buy rating on shares of 89bio (NASDAQ:ETNB – Free Report) in a research report sent to investors on Monday morning, Marketbeat.com reports. Bank of America currently has a $30.00 price objective... More of this article »
Euronet Worldwide (NASDAQ:EEFT) Upgraded to Buy by Citigroup
Citigroup upgraded shares of Euronet Worldwide (NASDAQ:EEFT – Free Report) from a neutral rating to a buy rating in a research report released on Monday morning, MarketBeat Ratings reports. They currently have $120.00 target... More of this article »
Enphase Energy (NASDAQ:ENPH) Given New $149.00 Price Target at B. Riley
Enphase Energy (NASDAQ:ENPH – Free Report) had its price objective increased by B. Riley from $121.00 to $149.00 in a research note issued to investors on Monday, Benzinga reports. The firm currently has a buy rating on the semiconductor... More of this article »
Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target Increased to $36.00 by Analysts at JPMorgan Chase & Co.
Day One Biopharmaceuticals (NASDAQ:DAWN – Free Report) had its price target raised by JPMorgan Chase & Co. from $32.00 to $36.00 in a research report report published on Monday morning, Benzinga reports. JPMorgan Chase &... More of this article »
Eagle Bancorp Montana (NASDAQ:EBMT) Now Covered by Analysts at Hovde Group
Hovde Group started coverage on shares of Eagle Bancorp Montana (NASDAQ:EBMT – Free Report) in a research report released on Monday, StockNewsAPI reports. The firm issued a market perform rating and a $14.00 target price on the... More of this article »
Citizens & Northern (NASDAQ:CZNC) Upgraded to “Hold” by StockNews.com
StockNews.com upgraded shares of Citizens & Northern (NASDAQ:CZNC – Free Report) from a sell rating to a hold rating in a report issued on Monday. Separately, TheStreet lowered Citizens & Northern from a b- rating to... More of this article »
Community West Bancshares (NASDAQ:CWBC) Lowered to Sell at StockNews.com
StockNews.com lowered shares of Community West Bancshares (NASDAQ:CWBC – Free Report) from a hold rating to a sell rating in a report issued on Monday. Several other research analysts have also recently weighed in on CWBC. Keefe,... More of this article »
Community West Bancshares (NASDAQ:CWBC) Price Target Lowered to $22.00 at Keefe, Bruyette & Woods
Community West Bancshares (NASDAQ:CWBC – Free Report) had its price objective trimmed by Keefe, Bruyette & Woods from $23.00 to $22.00 in a research report released on Monday, Benzinga reports. The brokerage currently has... More of this article »
Cyclo Therapeutics (NASDAQ:CYTH) Now Covered by Analysts at Ascendiant Capital Markets
Ascendiant Capital Markets began coverage on shares of Cyclo Therapeutics (NASDAQ:CYTH – Free Report) in a report issued on Monday morning, Benzinga reports. The brokerage issued a buy rating and a $2.60 target price on the stock. Cyclo... More of this article »